Non-Small Cell Lung Cancer Market Size, Share, Global Insights and Analysis

According to Global Markets Direct's, recently published report 'Non-Small Cell Lung Cancer – Pipeline Review, H1 2016'; Non-Small Cell Lung Cancer pipeline therapeutics constitutes close to 577 molecules. Out of which approximately 520 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; Non-Small Cell Lung Cancer Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

The report 'Non-Small Cell Lung Cancer – Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Browse full report with TOC@ https://marketreportscenter.com/reports/338302/non-small-cell-lung-cancer-pipeline-review-h1-2016

It also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 42, 163, 135, 10, 139, 19 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 11, 4, 1, 33...